Longitudinal multi-omic platelet volunteer program
Official title: Platelet Volunteers, Longitudinal and Multi-omic Study
Run by National Institutes of Health Clinical Center (CC) · NCT07137429 · Data updated 2026-11-12
This program will collect regular blood samples and health data from healthy adults to test how platelets, genes, and proteins change over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | March 26, 2026 |
| Main results expected | September 15, 2041 |
| Study ends | September 15, 2041 |
| Registry record updated | July 31, 2026 |
| Trial ID | NCT07137429 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults age 18 or older who can fast for blood draws, refrain from aspirin/NSAIDs when required, and commit to clinic visits every 6–7 months for up to 10 years.
✕Probably not a fit
People with active cancer, known autoimmune disease, major cardiovascular disease, active significant bleeding history, current pregnancy or lactation, or those on regular antiplatelet medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This longitudinal observational program enrolls healthy adults and collects blood, urine, physical exams, and questionnaire data every 6–7 months for up to 10 years. Samples will be used for platelet functional assays (platelet aggregation, hemostasis measurements) and for multi-omic profiling including DNA methylation, RNA-seq, proteomics, whole genome sequencing, plus in vitro iPSC work and imaging. Participants are asked to fast before visits and avoid aspirin/NSAIDs for seven days prior to blood draws to standardize results. The study aims to characterize normal variability in platelet-related measures and their association with lifestyle, anthropometrics, medications, and new health events.
Why it matters
Potential benefit: If successful, this could define normal platelet biology and variability, enabling better diagnostics and more targeted treatments for clotting and bleeding problems.
How similar studies have gone: Cross-sectional platelet and biobank studies have provided useful baseline data, but long-term multi-omic longitudinal profiling of healthy platelet function is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures, including fasting at least 10 hours before each blood draw * Stated willingness to refrain from aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) for 7 days prior to any visits * Age \>= 18 years * In good general health as evidenced by self-reported medical history EXCLUSION CRITERIA: An individual who, by self-report, meets the following criteria will be excluded from participation in this study: * Current pregnancy or lactation * Active malignancies known, active known auto-immune disease, known major CVD (e.g., heart attack, stroke, venous thromboembolism, heart failure), severe bleeding history, on regular P2Y12 inhibitors or other antiplatelet treatments for a clinical reason, uncontrolled hypertension or diabetes
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Andrew D Johnson, Ph.D. — National Heart, Lung, and Blood Institute (NHLBI)
- Study coordinator: Jayson J Grey, R.N.
- Email: jayson.grey@nih.gov
- Phone: (240) 401-6378
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Thromboelastometry to Predict Thrombosis and Survival in Glial Tumor Surgery
Aimed at people with glial tumors undergoing surgery, the study tests whether thromboelastometry and other blood tests can predict blood-clot risk and survival.
-
Personalized blood-thinner plan for leg artery disease after repair
A personalized plan using a blood test to tailor antiplatelet therapy is being tested against standard treatment in adults with PAD after a procedure to restore blood flow.
-
Multi-omics search for clotting and bleeding markers in coronary heart disease
This project will test whether combining proteins, metabolites, genes, sugar tags, and heart images can better predict clotting and major bleeding in people with coronary heart disease on dual antiplatelet therapy.
-
Gruticibart to Prevent Catheter-Related Blood Clots
This phase II trial tests whether a single dose of gruticibart can prevent blood clots caused by a central venous catheter in adults.
-
Apixaban vs Warfarin in HeartMate 3 LVAD Patients
This study tests whether apixaban can replace warfarin to prevent clots and bleeding problems in adults with an implanted HeartMate 3 LVAD for at least 3 months.
-
Safety of perioperative blood thinner management in people with cancer undergoing surgery or procedures
This study tests how safe current practices are for stopping or continuing blood thinners in adults with cancer who are having surgery or procedures, to see if bleeding or clots are affected.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.